Nature Communications Paper for Roland Schüle and team
“Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity”
The CRC 992 »Medical Epigenetics« (MEDEP) was a DFG-sponsored research consortium that was established in July 2012 and completed in June 2024. MEDEP did provide a translational program for epigenetic research through teams from the University Freiburg Medical Centre, the University of Freiburg and the Max Planck Institute of Immunobiology and Epigenetics.
The following pages give you an overview of the research activities and achievements throughout the 12-year funding period.